A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
| Protocol No. | CTO-BTCRC-LUN18-153 | Scope | National |
|---|---|---|---|
| Principal Investigator | Greg Durm | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase II |
